✦ LIBER ✦

HIGH-DOSE MELPHALAN FOR MULTIPLE MYELOMA

✍ Scribed by Cavo, Michele; Baccarani, Michele; Gobbi, Marco; Tura, Sante

Book ID: 122784266
Publisher: The Lancet
Year: 1983
Tongue: English
Weight: 165 KB
Volume: 322
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(83)91240-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of Body Composition and Renal Fun

Effect of Body Composition and Renal Function on the Pharmacokinetics of High-Dose Melphalan for Multiple Myeloma

✍ D.T. Vogl; R. Mick; E. Stoopler; L.E. Davis; T.M. Paul; G. Salazar; M. Raguza-Lo 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB

CD4+ CD28+ lymphocytes on day 5 after hi

CD4+ CD28+ lymphocytes on day 5 after high-dose melphalan for multiple myeloma predict a low risk of infections during severe neutropenia and are associated with the number of reinfused T lymphocytes of the autologous stem cell graft

✍ Schmidmaier, Ralf; Then, Cornelia; Schnabel, Brigitte; Oduncu, Fuat; Baumann, Ph 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 198 KB

19: Arsenic trioxide with ascorbic acid

19: Arsenic trioxide with ascorbic acid and high-dose melphalan for autologous hematopoietic stem cell transplantation for multiple myeloma

✍ M.H. Qazilbash; S. Jindani; Z. Gul; R. Saliba; C. Hosing; F. Mendoza; S.P. Qures 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 68 KB

A Phase 2 Study of Bortezomib Plus High-

A Phase 2 Study of Bortezomib Plus High-Dose Melphalan Conditioning for Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

✍ T. Nishihori; J.L. Ochoa-Bayona; J. Pidala; K. Shain; R. Baz; C.M. Simonelli; D. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 49 KB

High-dose idarubicine, busulphan and mel

High-dose idarubicine, busulphan and melphalan as conditioning for autologous blood stem cell transplantation in multiple myeloma. A feasibility study

✍ Meloni, G; Capria, S; Trasarti, S; Ferrazza, G; Micozzi, A; Petrucci, M T; Simon 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 57 KB

Comparison of high-dose melphalan with a

Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma

✍ Athanasios Anagnostopoulos; Ana Aleman; Gregory Ayers; Michele Donato; Richard C 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB

## Abstract ## BACKGROUND High‐dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) as part of the initial treatment regimen improves progression‐free survival (PFS) and overall survival (OS) for patients with multiple myeloma. The optimal preparative regimen for patients with